Use of influenza A (H1N1) 2009 monovalent vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009
National Center for Immunization and Respiratory Diseases
National Center for Immunization and Respiratory Diseases. Use of influenza A (H1N1) 2009 monovalent vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.MMWR Morb Mortal Wkly Rep 2009; 58:1-8.
World Health Organization (WHO) December 04 Accessed 7 April 2010
World Health Organization (WHO). Global alert and response (GAR). Pandemic influenza A (H1N1) 2009 virus vaccinedconclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts, December 04, 2009. Available at: http://www.who.int/csr/disease/ swineflu/meetings/sage-oct-2009/en/. Accessed 7 April 2010.
World Health Organization (WHO) briefing note 2 Accessed 8 March 2010
World Health Organization (WHO). WHO recommendations on pandemic (H1N1) 2009 vaccines. Pandemic (H1N1) 2009: briefing note 2. Available at: http://www.who.int/csr/disease/swineflu/notes/h1n1-vaccine-20090713/en/index. html. Accessed 8 March 2010.
Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults
Chu DW, Hwang SJ, Lim FS, et al. Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults. Vaccine 2009; 27: 7428-4235.
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial
DOI 10.1016/S0140-6736(07)61297-5, PII S0140673607612975
Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9. (Pubitemid 47247854)
Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine
Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3:e1665.
Ten years of experience with the trivalent split-influenza vaccine, Fluarix™
Hehme NW, Künzel W, Petschke F, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix. Clin Drug Invest 2002; 22:751-69. (Pubitemid 35388185)
European Committee for Proprietary Medicinal Products (CHMP) European Agency for the Evaluation of Medicinal Products
European Committee for Proprietary Medicinal Products (CHMP). Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, 2007.
US Food and Drug Administration (FDA) Accessed 5 January 2010
US Food and Drug Administration (FDA). Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration, 2007. Available at: http://www.fda.gov/cber/gdlns/ panfluvac.htm. Accessed 5 January 2010.
Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccinedpreliminary report
Clark TW, Pareek M, Hoschler K, et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccinedpreliminary report. N Engl J Med 2009; 361:2424-35.
Response after one dose of a monovalent influenza A (H1N1) 2009 vaccinedpreliminary report
Greenberg ME, Lai MH, Hartel GF, et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccinedpreliminary report. N Engl J Med 2009; 361:2405-13.
Safety and immunogenicity of2009 pandemic influenza A H1N1 vaccines in China: A multicentre, double-blind, randomised, placebo-controlled trial
Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375:56-66.
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)-trial. adjuvant: Preliminary report of an observer-blind, randomized controlled trial
Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)-trial. adjuvant: preliminary report of an observer-blind, randomized controlled trial. Vaccine 2010; 28:1740-5.
